Th17 cells contribute to steroid-resistant airway inflammation and airway hyperresponsiveness in mice model [32], and hence abatacept, by targeting IL-17 signaling, could improve responsiveness to steroid therapy in these steroid hypo-responsive patients. Here, IL17A is linked to airway hyperresponsiveness.